Given that Src signalling has been previously implicated in promoting chemoresistance in ovarian cancer [13,23,24], in the present study we aimed to investigate the CSC-mediated anti-tumour activity of Dasatinib, alone and in combination with paclitaxel in vitro and in vivo. This evidence concerns the gene SRC and ovarian cancer.